Mechanical thrombectomy for acute ischaemic stroke, part 2. Health economic evaluation

Stoinska-Schneider A, Robberstad B, Fure B.
Record ID 32018000798
English, Norwegian
Original Title: Mekanisk trombektomi ved akutt hjerneinfarkt - del 2
Authors' objectives: Our objective was to assess cost-effectiveness of mechanical thrombectomy as additional treatment to standard therapy (thrombolysis) compared with standard treatment alone in the Norwegian settings, as well as to perform a budget impact analysis.
Authors' results and conclusions: The results of our base case analysis indicate that: • Treatment with thrombectomy was associated with more quality-adjusted life-years (QALYs). • Treatment with thrombectomy was somewhat more costly than standard treatment in lifetime perspective. • The incremental cost per QALY gained of thrombectomy over a 25 year period was 12,034 kroner per QALY gained#. In the scenario analysis we assumed investment costs of 10 million kroner for establishing two new centres for treatment with thrombectomy, as well as improved time to treatment (up to five hours from symptom onset). We have found that: • Treatment with thrombectomy was associated with more quality-adjusted life-years (QALYs). • Treatment with thrombectomy was more costly than standard treatment in lifetime perspective. • The incremental cost per QALY gained of thrombectomy over a 25 year period was 77,233 kroner per QALY gained. Results of our sensitivity analysis indicate that cost parameters had the greatest impact on the results. Nowadays, about 150 patients in Norway receive treatment with thrombectomy annually. Results of the budget impact analysis show that increasing the number of patients treated with thrombectomy to 450, would be associated with an incremental costs of about 18 million kroner with the assumption of sufficiency of the existing capacity. Our cost-utility analysis indicates that mechanical thrombectomy as additional treatment for patients with ischaemic stroke with occlusion of the big blood vessels, is cost-effective compared with standard treatment alone.
Authors' methods: We performed a cost-utility analysis (CUA) where relevant costs were expressed in Norwegian kroner (NOK) and effects were expressed in quality-adjusted life-years (QALYs). The analysis was carried out in a healthcare perspective. A decision analytic model of the Markov type, in which a cohort of patients is followed over a given period of time, was developed in TreeAge Pro® 2016. The results were expressed as mean incremental cost-effectiveness ratio (ICER). Uncertainties in model parameters were handled by performing one way (Tornado diagram) and probabilistic sensitivity analyses, designed as a Monte Carlo simulation, with 10 000 iterations. Additionally, a scenario analysis was performed, where increased costs of investment in establishing of two new centres for treatment with thrombectomy were assumed, along with the assumption about all eligible patients treated within 5 hours from symptom onset. We have also performed a budget impact analysis of implementation of thrombectomy as a routine treatment based on the cost results of the cost-utility analysis.
Details
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Norway
MeSH Terms
  • Thrombectomy
  • Stroke
  • Cost-Benefit Analysis
  • Brain Ischemia
  • Ischemia
  • Mechanical Thrombolysis
  • Thrombolytic Therapy
Keywords
  • Mechanical thrombectomy
  • Acute ischemic stroke
  • Cost‐effectiveness analysis
Contact
Organisation Name: Norwegian Institute of Public Health
Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.